Compare Citius Pharmaceuticals Inc (CTXR) vs HF Sinclair Corporation Common Stock (DINO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs HF Sinclair Corporation Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while HF Sinclair Corporation Common Stock trades at $121.3 (market cap $21.46B). The key difference: HF Sinclair Corporation Common Stock is far larger — about 1575.6× Citius Pharmaceuticals Inc's market cap, and HF Sinclair Corporation Common Stock pays a 1.74% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and HF Sinclair Corporation Common Stock for 0 Days on average.
| CTXR | DINO | |
|---|---|---|
Market Cap | $13.62M | $21.46B |
Volume | 132,438 | 2,430,580 |
Sector | Health | Energy |
52-Week High | $1.82 | $120.72 |
52-Week Low | $0.48 | $45.88 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $3.79M | $22.44B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About HF Sinclair Corporation Common Stock
HF Sinclair refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics and renewable fuels businesses.
Read more on DINO →
